DBI
DBI (diazepam binding inhibitor, acyl-CoA binding protein), also known as ACBP or ACBD1, is a small intracellular protein that binds medium- and long-chain acyl-CoA esters with very high affinity. It can also displace diazepam from the benzodiazepine site on the GABA type A receptor. Browse Assay Genie's current range of DBI research reagents below, or read on for the biology behind the target.
DBI binds medium- and long-chain acyl-CoA esters with very high affinity and may act as an intracellular carrier of these esters. The most highly conserved region of the protein is a stretch of seven contiguous residues that forms the hydrophobic binding site for acyl-CoA esters, and this feature is conserved from yeast to mammals. DBI is also able to displace diazepam from the benzodiazepine (BZD) recognition site on the GABA type A receptor, so it may additionally act as a neuropeptide that modulates GABA receptor activity.
The human DBI gene encodes a protein that is regulated by hormones and is involved in lipid metabolism. According to the NCBI Gene summary, it takes part in displacing beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors in brain synapses. UniProt lists the protein in the endoplasmic reticulum and Golgi apparatus, and places it in the ACBP family. Multiple transcript variants encoding different isoforms have been described, and three pseudogenes are known on chromosomes 6, 8 and 16.
Beyond lipid handling and GABA signalling, DBI mediates feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin. It also acts as a mediator in corticotropin-dependent adrenal steroidogenesis. The gene was originally named diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein), and the aliases ACBP and ACBD1 reflect its two best-characterised activities. Researchers studying the DBI protein can work in mouse and rat, which each carry a Dbi ortholog.
DBI binds medium- and long-chain acyl-CoA esters and may carry them within the cell, making it relevant to studies of lipid metabolism.
DBI displaces benzodiazepines and beta-carbolines at the GABA type A receptor and may act as a neuropeptide modulating receptor function.
DBI mediates feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin.
DBI acts as a mediator in corticotropin-dependent adrenal steroidogenesis, linking hormonal control to steroid production.
DBI binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an intracellular carrier of them. It can also displace diazepam from the benzodiazepine site on the GABA type A receptor, suggesting a role as a neuropeptide modulating GABA receptor action.
DBI stands for diazepam binding inhibitor, acyl-CoA binding protein. Aliases include ACBP and ACBD1, and UniProt names the protein acyl-CoA-binding protein. The earlier HGNC name was diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein). Multiple transcript variants encoding different isoforms have been described.
Yes. The protein is conserved from yeast to mammals, and its most conserved domain is a seven-residue hydrophobic binding site for medium- and long-chain acyl-CoA esters. Mouse and rat both have a Dbi ortholog. Check the datasheet of any product for its validated reactivity.
Other acyl-CoA-binding proteins, GABA receptor subunits and hormone-pathway targets linked to DBI biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P07108; product specifications from Assay Genie datasheets.